STOCK TITAN

Twist Bioscience (TWST) Form 144 Filed for 1,840-Share Sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filed for Twist Bioscience Corporation (TWST) reporting an intended sale of common stock. The notice shows 1,840 shares to be sold through Fidelity Brokerage Services with an aggregate market value of $47,774.13 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 via restricted stock vesting and relate to compensation. The issuer has 60,360,925 shares outstanding per the form. Recent disposals by the same person, Patrick Finn, are listed: 1,877 shares (05/21/2025, $55,835.87), 209 shares (07/02/2025, $7,564.36), 2,232 shares (07/23/2025, $79,773.02), and 3,189 shares (08/04/2025, $90,453.11).

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale from restricted stock vesting; amounts are small relative to outstanding shares and appear non-material.

The filing documents a proposed sale of 1,840 common shares by an insider via a broker, acquired the prior day through restricted stock vesting and characterized as compensation. The form also discloses four prior small sales totaling 7,507 shares over the past three months with disclosed gross proceeds. Compared with the reported 60,360,925 shares outstanding, these transactions represent an immaterial ownership shift and are consistent with typical post-vesting selling activity rather than a company-level development.

TL;DR: Disclosure aligns with Rule 144 requirements; signer affirms no undisclosed material information.

The notice includes the required Rule 144 details: acquisition date, nature of acquisition (restricted stock vesting), broker name, and recent sales history for the reporting person, Patrick Finn. The signature/representation language affirms absence of undisclosed material information. There is no indication of a trading plan date on the form, and nothing in this filing signals governance changes or regulatory concerns.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

Who is selling TWST shares on this Form 144?

The filing identifies the seller as Patrick Finn, with multiple recent sales and a proposed sale reported on this form.

How many TWST shares are proposed for sale and when?

The notice reports 1,840 common shares to be sold with an approximate sale date of 08/21/2025.

How were the 1,840 shares acquired?

The shares were acquired on 08/20/2025 through restricted stock vesting and the consideration is listed as compensation.

What recent insider sales by the same person are disclosed?

The form lists four prior sales by Patrick Finn in the past three months totaling 7,507 shares on 05/21/2025, 07/02/2025, 07/23/2025, and 08/04/2025 with the corresponding gross proceeds shown.

What is the aggregate market value and shares outstanding reported?

The aggregate market value for the proposed sale is $47,774.13, and the form reports 60,360,925 shares outstanding.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.77B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO